CRISPR Therapeutics AG

SecurityCRSP / CRISPR Therapeutics AG
InstitutionBarclays Plc
Latest Disclosed Ownership0 shares
Latest Disclosed Value $ 0
Barclays Plc ownership in CRSP / CRISPR Therapeutics AG

On May 15, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 0 shares of CRISPR Therapeutics AG (US:CRSP) valued at $0 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 249,988 shares of CRISPR Therapeutics AG. This represents a change in shares of -100.00% during the quarter. The current value of the position is $0 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (CRSP) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

CRSP / CRISPR Therapeutics AG Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS COM H17182108 0 -249,988 -100.00 0 -100.00
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS COM H17182108 249,988 -99,863 -28.54 13,109 -42.18 0.0031
2026-03-31 2025-09-30 13F/A-3 CRISPR THERAPEUTICS COM H17182108 349,851 -30,772 -8.08 22,674 22.47 0.0049
2026-03-19 2025-09-30 13F/A-2 CRISPR THERAPEUTICS COM H17182108 129,848 -250,775 6,100 0.0016
2025-11-12 2025-09-30 13F CRISPR THERAPEUTICS COM H17182108 349,851 -30,772 22,674 0.0049
2026-02-27 2025-06-30 13F/A-2 CRISPR THERAPEUTICS COM H17182108 380,623 290,997 324.68 18,514 507.18 0.0042
2025-08-14 2025-06-30 13F/A-1 CRISPR THERAPEUTICS COM H17182108 380,623 290,997 19 0.0042
2025-08-13 2025-06-30 13F CRISPR THERAPEUTICS COM H17182108 380,623 290,997 19 0.0014
2026-03-17 2025-03-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 89,626 -12,432 -12.18 3,050 -24.10 0.0009
2025-05-15 2025-03-31 13F CRISPR THERAPEUTICS COM H17182108 89,626 -12,432 3 0.0009
2026-03-19 2024-12-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 102,058 -27,790 -21.40 4,017 -34.15 0.0011
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS COM H17182108 102,058 -27,790 4 0.0011
2026-03-31 2024-09-30 13F/A-2 CRISPR THERAPEUTICS COM H17182108 129,848 64,228 97.88 6,100 72.12 0.0016
2024-11-19 2024-09-30 13F/A-1 CRISPR THERAPEUTICS COM H17182108 129,848 64,228 6 0.0016
2024-11-15 2024-09-30 13F CRISPR THERAPEUTICS COM H17182108 129,848 64,228 6 0.0016
2026-03-23 2024-06-30 13F/A-1 CRISPR THERAPEUTICS COM H17182108 65,620 -190,711 -74.40 3,544 -79.71 0.0011
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS COM H17182108 65,620 -190,711 4 0.0011
2026-03-24 2024-03-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 256,331 -56,634 -18.10 17,472 -10.82 0.0061
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS COM H17182108 256,331 -56,634 17 0.0061
2026-03-25 2023-12-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 312,965 -197,867 -38.73 19,592 -15.51 0.0072
2024-02-15 2023-12-31 13F CRISPR THERAPEUTICS COM H17182108 312,965 -197,867 20 0.0072
2026-03-26 2023-09-30 13F/A-1 CRISPR THERAPEUTICS COM H17182108 510,832 137,629 36.88 23,187 10.67 0.0144
2023-11-07 2023-09-30 13F CRISPR THERAPEUTICS COM H17182108 510,832 137,629 23 0.0144
2026-03-30 2023-06-30 13F/A-2 CRISPR THERAPEUTICS COM H17182108 373,203 11,444 3.16 20,952 28.05 0.0133
2023-09-20 2023-06-30 13F/A-1 CRISPR THERAPEUTICS COM H17182108 373,203 11,444 21 0.0133
2023-08-03 2023-06-30 13F CRISPR THERAPEUTICS COM H17182108 373,203 11,444 21 0.0132
2026-03-30 2023-03-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 361,759 -27,918 -7.16 16,362 3.30 0.0075
2023-05-04 2023-03-31 13F CRISPR THERAPEUTICS COM H17182108 361,759 -27,918 16 0.0075
2026-03-30 2022-12-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 389,677 280,911 258.27 15,840 122.85 0.0071
2023-02-13 2022-12-31 13F CRISPR THERAPEUTICS COM H17182108 389,677 280,911 16 0.0071
2022-11-03 2022-09-30 13F CRISPR THERAPEUTICS COM H17182108 108,766 87,117 402.41 7,108 439.71 0.0078
2022-08-12 2022-06-30 13F CRISPR THERAPEUTICS COM H17182108 21,649 4,025 22.84 1,317 18.97 0.0008
2022-05-16 2022-03-31 13F CRISPR THERAPEUTICS COM H17182108 17,624 3,453 24.37 1,107 3.17 0.0009
2022-02-23 2021-12-31 13F/A-1 CRISPR THERAPEUTICS COM H17182108 14,171 -18,859 -57.10 1,073 -70.98 0.0004
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS COM H17182108 14,171 -18,859 1,073 0.0004
2021-11-09 2021-09-30 13F CRISPR THERAPEUTICS COM H17182108 33,030 12,006 57.11 3,697 8.67 0.0017
2021-08-13 2021-06-30 13F CRISPR THERAPEUTICS COM H17182108 21,024 15,224 262.48 3,402 381.87 0.0016
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS COM H17182108 5,800 -13,947 -70.63 706 -76.65 0.0004
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS COM H17182108 19,747 6,390 47.84 3,023 170.64 0.0016
2020-11-12 2020-09-30 13F CRISPR THERAPEUTICS COM H17182108 13,357 13,246 11,933.33 1,117 13,862.50 0.0007
2020-08-12 2020-06-30 13F CRISPR THERAPEUTICS COM H17182108 111 -37 -25.00 8 33.33 0.0000
2020-05-13 2020-03-31 13F CRISPR THERAPEUTICS COM H17182108 148 -5,161 -97.21 6 -98.15 0.0000
2020-02-10 2019-12-31 13F CRISPR THERAPEUTICS COM H17182108 5,309 -8,568 -61.74 324 -42.96 0.0002
2019-11-15 2019-09-30 13F/A-1 CRISPR THERAPEUTICS COM H17182108 13,877 4,151 42.68 568 23.75 0.0004
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS COM H17182108 13,877 4,151 568 131.3222
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS COM H17182108 9,726 -5,073 -34.28 459 -13.07 0.0003
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS COM H17182108 14,799 9,920 203.32 528 279.86 0.0004
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS COM H17182108 4,879 -7,302 -59.95 139 -74.31 0.0001
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS COM H17182108 12,181 -4,590 -27.37 541 -45.08 0.0004
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS COM H17182108 16,771 1,071 6.82 985 37.38 0.0008
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS COM H17182108 15,700 400 2.61 717 99.17 0.0005
2018-02-14 2017-12-31 13F CRISPR THERAPEUTICS COM H17182108 15,300 3,436 28.96 360 70.62 0.0003
2017-11-14 2017-09-30 13F CRISPR THERAPEUTICS COM H17182108 11,864 11,864 211 0.0002
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2026-03-19 2025-09-30 13F/A CRISPR THERAPEUTICS OPT Call 30,000 1,409 n/a n/a n/a
2026-03-19 2024-12-31 13F/A CRISPR THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS OPT Call 0 0 n/a n/a n/a
2024-11-19 2024-09-30 13F/A CRISPR THERAPEUTICS OPT Call 30,000 1 n/a n/a n/a
2026-03-31 2024-09-30 13F/A CRISPR THERAPEUTICS OPT Call 30,000 -73.68 1,409 -77.12 n/a n/a n/a
2024-11-15 2024-09-30 13F CRISPR THERAPEUTICS OPT Call 30,000 1 n/a n/a n/a
2026-03-23 2024-06-30 13F/A CRISPR THERAPEUTICS OPT Call 114,000 322.22 6,157 234.62 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS OPT Call 114,000 6 n/a n/a n/a
2026-03-24 2024-03-31 13F/A CRISPR THERAPEUTICS OPT Call 27,000 -48.08 1,840 -43.47 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS OPT Call 27,000 2 n/a n/a n/a
2026-03-25 2023-12-31 13F/A CRISPR THERAPEUTICS OPT Call 52,000 3,255 n/a n/a n/a
2024-02-15 2023-12-31 13F CRISPR THERAPEUTICS OPT Call 52,000 3 n/a n/a n/a
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS OPT Call 2,500 383 n/a n/a n/a
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS OPT Call 34,700 1,586 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-15 2026-03-31 13F CRISPR THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2026-02-13 2025-12-31 13F CRISPR THERAPEUTICS OPT Put 95,000 -34.71 4,982 -47.17 n/a n/a n/a
2026-03-31 2025-09-30 13F/A CRISPR THERAPEUTICS OPT Put 145,500 130.95 9,430 207.73 n/a n/a n/a
2026-03-19 2025-09-30 13F/A CRISPR THERAPEUTICS OPT Put 30,000 1,409 n/a n/a n/a
2025-11-12 2025-09-30 13F CRISPR THERAPEUTICS OPT Put 145,500 9,430 n/a n/a n/a
2025-08-14 2025-06-30 13F/A CRISPR THERAPEUTICS OPT Put 63,000 3 n/a n/a n/a
2026-02-27 2025-06-30 13F/A CRISPR THERAPEUTICS OPT Put 63,000 3,064 n/a n/a n/a
2026-03-19 2024-12-31 13F/A CRISPR THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-13 2024-12-31 13F CRISPR THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2024-11-19 2024-09-30 13F/A CRISPR THERAPEUTICS OPT Put 30,000 1 n/a n/a n/a
2026-03-31 2024-09-30 13F/A CRISPR THERAPEUTICS OPT Put 30,000 1,409 n/a n/a n/a
2024-11-15 2024-09-30 13F CRISPR THERAPEUTICS OPT Put 30,000 1 n/a n/a n/a
2026-03-23 2024-06-30 13F/A CRISPR THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F CRISPR THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2026-03-24 2024-03-31 13F/A CRISPR THERAPEUTICS OPT Put 40,700 -73.22 2,774 -70.85 n/a n/a n/a
2024-05-15 2024-03-31 13F CRISPR THERAPEUTICS OPT Put 40,700 3 n/a n/a n/a
2026-03-25 2023-12-31 13F/A CRISPR THERAPEUTICS OPT Put 152,000 9,515 n/a n/a n/a
2024-02-15 2023-12-31 13F CRISPR THERAPEUTICS OPT Put 152,000 10 n/a n/a n/a
2023-09-21 2023-06-30 13F/A CRISPR THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2026-03-30 2023-06-30 13F/A CRISPR THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-08-03 2023-06-30 13F CRISPR THERAPEUTICS OPT Put 0 0 n/a n/a n/a
2026-03-30 2023-03-31 13F/A CRISPR THERAPEUTICS OPT Put 100,000 50.15 4,523 67.09 n/a n/a n/a
2023-05-04 2023-03-31 13F CRISPR THERAPEUTICS OPT Put 100,000 5 n/a n/a n/a
2026-03-30 2022-12-31 13F/A CRISPR THERAPEUTICS OPT Put 66,600 2,707 n/a n/a n/a
2023-02-13 2022-12-31 13F CRISPR THERAPEUTICS OPT Put 66,600 3 n/a n/a n/a
2021-05-13 2021-03-31 13F CRISPR THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2021-02-11 2020-12-31 13F CRISPR THERAPEUTICS OPT Put 2,500 383 n/a n/a n/a
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS OPT Put 59,500 168.02 3,496 244.43 n/a n/a n/a
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS OPT Put 22,200 1,015 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.